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Abstract  
 
Introduction/Objectives:  
Despite some concerns that the introduction of telehealth (TH) may lead to reductions in quality of 
life (QoL), lower mood and increased anxiety in response to using assistive technologies to reduce 
health care utilisation and manage long term conditions, this research focuses on the extent to 
which providing people with tools to monitor their condition can improve QoL.  
 
Methods:  
The Chronic Obstructive Pulmonary Disease cohort of the Whole Systems Demonstrator Trial is a 
pragmatic General Practitioner (GP) clustered RCT evaluating TH in the UK from three regions in 
England. All patients at a participating GP practice were deemed eligible for inclusion in the study if 
they were diagnosed with COPD.  
 
Results:  
447 participants completed baseline and either a short (4 months) or long term (12 months) follow 
up. There was a trend of improved QoL and mood in the TH group at longer-term follow up, but not 
short term follow up. Emotional functioning (g= 0.280 95% CI, 0.051- 0.510) and mastery reached (g= 
2.979 95%CI, 0- 0.46) significance at P<0.05 (all Hedges g <0.3).  
 
Conclusions:  
TH showed minimal benefit to QoL in COPD patients who were not preselected to be at increased 
risk of acute exacerbations.  Benefits were more likely in disease specific measures at longer term 
follow up. TH is a complex intervention and should be embedded in a service that is evidenced 
based. Outcome measures must be sensitive enough to detect changes in the target population for 
the specific intervention.  
Keywords: Telehealth, self-monitoring, self-management, Quality of life, Patient Reported Outcomes (PRO), COPD  
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Introduction  
Chronic obstructive pulmonary disease (COPD) leads to a number of disabling and distressing 
symptoms with patients’ quality of life (QoL) showing declines over time (1). COPD is 
associated with a greater risk of anxiety (2) and depression (3) and in turn higher anxiety is 
associated with a greater risk of exacerbations, (2) while depression is associated with a 
greater incidence of hospitalisation (3). 
Despite some concerns that Telehealth (TH) may lead to social isolation and reductions in 
QoL the focus of work has been on examining whether TH leads to improvements in QoL.  In 
COPD there is limited available evidence on the impact of TH on QoL. Systematic reviews 
have found a limited number of randomised controlled trials (RCTs) that examined the 
effectiveness of TH on QoL in patients with COPD(4) and those that have identified evidence 
have found mixed results on various QoL measures,(5) as well as other outcomes such as 
healthcare utilisation (6, 7).  
A Cochrane review (8) reported on two RCTs measuring QoL. (9, 10) These studies included 
254 patients with COPD and indicated minimally clinically significant improvement in 
symptoms, activity levels, and impact on patient’s QoL. However, the confidence intervals 
were wide and 2 studies were insufficient for sub-group analysis, or meta-regression to 
examine what factors might influence the effect of TH on patient outcomes.  
A more recent RCT of TH on 256 COPD patients reported no benefits at 12-months on the 
QoL, mood or self-efficacy regarding management of their condition. Sub-group analysis 
indicated that the effect of TH on hospital admission was not affected by demographic 
factors or mood, but was less effective for participants with mild or moderate COPD (11).  
The current aim of the investigation focuses on the COPD cohort of the Whole System 
Demonstrator (WSD), for which there are still relatively few methodologically robust trials 
evaluating the effectiveness of TH.  
Methods 
Design  
WSD is one of the largest pragmatic cluster randomised controlled trials evaluating TH in the 
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UK (12). Patients with COPD from Cornwall, Kent and Newham were recruited from 121 
General Practices. Cluster randomisation was performed by the Trial statistician, balancing 
for region, practice size, deprivation index, ethnicity and prevalence of COPD to receive 
either standard care or the TH intervention. The study was approved by Liverpool Research 
Ethics Committee (ref: 08/H1005/4). Recruitment took place between May 2008 and 
December 2009, final 12-month follow-ups were conducted in December 2010. (Figure 1).   
 
Participants   
All patients at a participating GP practice were deemed eligible for inclusion in the study if 
they were diagnosed with COPD.  Diagnosis could either be by inclusion on the relevant 
Quality Outcomes Framework (QOF) register in primary care, had a confirmed medical 
diagnosis as indicated by GP Read Codes or ICD-10 codes, or a confirmed diagnosis by the 
patients local clinician (i.e. GP, community matron or hospital consultant). Eligible 
participants also needed to have a landline telephone and broadband internet connection, 
and in Newham a digital television, as well as sufficient cognitive capacity and English 
language skills to complete a self-reported questionnaire.  Five-hundred and seventy-eight 
patients with COPD completed questionnaires assessing a range of patient reported 
outcomes.  
TH Intervention  
Participants in the trial arm received a pulse oximeter + blood pressure monitor, weight 
scales, and additional peripherals depending on clinical need. For example, a glucometer for 
patients who also suffered with diabetes.  The peripheral devices were attached to a home 
monitoring system comprising a base unit with an LCD screen to allow questions about 
health and educational messages to be transmitted to participants, or set-top box that 
connected to a television allowing symptom questions, educational videos and a graphical 
history of clinical readings.  Data was transmitted by participants to a monitoring centre, 
where it was reviewed by healthcare professionals. This would then trigger an appropriate 
response such as doing nothing; requesting a repeat reading, contacting the participant or 
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their named informal carer, arranging a home visit by their community matron or referring 
on to another healthcare service (please see (13) for further details).  
Standard Care (control group) 
The standard care group were told they would be offered TH services at the end of the trial, 
providing they were still eligible. 
Outcome measures   
Patient reported outcome measures included three QoL instruments. The Chronic 
Respiratory Questionnaire (CRQ) (14) measured perceived mastery of disease, fatigue, 
emotional impact of the disease and dyspnoea. The SF12- general health status comprised 
of two subscales, Physical Component Summary score (PCS) & the Mental Component 
Summary score (MCS) (1). The EQ-5D (15) a measure of health status with questions 
pertaining to mobility, self-care, usual activates, pain/discomfort and anxiety/depression.  
Additionally, anxiety and depression were measured by the Brief State Trait Anxiety 
Inventory STAI-6 (16) and the Center for Epidemiologic Studies Depression Scale CESD-10 
(17). 
Sample size calculation  
550 participants were required to detect a clinically meaningful difference of 0.3 ( standard 
deviation of 1.0) on the CRQ (small effect size), (18) allowing for an intra-cluster correlation 
coefficient of 0.05, power of 80% and an alpha of p <0.05, with the addition of a 10% 
inflation to allow for the maximum possible increase in sample size due to variable cluster 
size (19).  
Procedure  
Following agreement from the GP practices, eligible patients were sent a data sharing 
consent form giving the researchers access to their medical records. A consecutive sample 
was invited to consent to participate in the study.  Baseline questionnaires were completed 
with a trained interviewer. Participants allocated to the TH intervention had equipment 
installed into their homes by the local WSD teams. The control group continued with 
standard care for the duration of the trial. Follow-up questionnaire assessments were 
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conducted at 4-months (short-term follow-up) and 12-Months (long-term follow-up). Two 
reminders to complete the postal questionnaires were made, unless they withdrew.  
Statistical methods  
Missing data were imputed 10 times for variables where participants had provided at least 
50% of the responses using the SPSS Markov Chain Monte Carlo imputation function. Multi-
level modelling analysis using linear mixed model procedures in SPSS were conducted on all 
10 imputed datasets. To account for differences between GP practices, the outcomes 
measure at different time points (time) were nested within participants (cases), which in 
turn were nested within GP practices (unit of randomisation). Random intercepts were used 
at the GP practice level, and trial arm and time were entered as fixed effects along with a 
trial arm x time interaction, with the addition of covariates. The covariates included were 
age, gender, ethnicity, educational attainment, postcode determined Index of Multiple 
Deprivation score (20), number of co-morbidities recorded from hospital records, the WSD 
region (Cornwall, Kent, and Newham), the number of days between TH installation and 
questionnaire completion and the baseline measure of the dependent variable.   
Standard multiple imputation procedures were used to combine the multiple outputs (21-
23) using SPSS (v.19) and NORM. (24) Analysis were repeated for each of the outcome 
variables and for (i) those who completed both short and long-term follow-up 
questionnaires (Complete Case Cohort CCC) and (ii) a larger dataset utilising anyone who 
completed either a short or long-term follow-up (Available Case Cohort ACC). This process 
was then repeated on a dataset excluding all cases where there had been a protocol 
violation (per-protocol analysis) to examine whether the results were sensitive to change 
depending on the analysis.  
 
Results  
The participant flow from GP clusters into intervention and control groups are shown in 
Figure 1. Socio-demographic characteristics are displayed in Table 1, for the baseline, ACC 
and CCC. The effect of TH on healthcare utilisation has been reported elsewhere (25), but in 
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the baseline COPD cohort, ACC and CCC, the frequency of emergency hospitalisation was 
marginally higher in the usual care in both ACC and CCC (chi-square P>0.05).  
 
There were 447 participants completing baseline and either a short or long term follow-up 
and 314 completing all three questionnaire assessments.  
Emotional functioning significantly improved in the TH intervention group (mean 3·344 to 
4·964) compared to the control group (mean 3·776 to 3·871) over time in the available case 
cohort (F= 4·341, P<0·040) and the complete case cohort (mean 2·7079 to 5·504 in the 
intervention group and 3·139 to 3·267 in the control group, F = 10·572, P<0·001). In the 
complete case analysis cohort emotional functioning was significantly higher in the TH group 
compared to the control group (5·504 compared to 3·267, F = 6·696, P<0·010, g =0.280, 95% 
CI 0.051- 0.510), but did not reach significance in the available case cohort (4·964 compared 
to 3·871, F = 1·117, P<0·293, g = 0.11, 95% CI -0.08-0.30) (tables 2 and 3).   
 
Mastery over managing COPD significantly improved over time in the TH intervention group 
(3·290 to 5·795) compared to the control group (3·600 to 3·640) in the complete case cohort 
(F = 5·981, P<0·041), but not the available case (4·308 to 5·335 in the intervention group and 
4·490 to 4·512 in the control group, (F = 1·346, P<0·248). Mastery was significantly higher in 
the TH intervention group compared to the control group (5·795 compared to 3·640, F = 
4·323, P<0·038, g = 2.979, 95% CI 0-0.46), but again this was only for participants completing 
all three questionnaire assessments and was not observed in the available case cohort 
(5·335 compared to 4·512, F = 1·003, P<0·318, g = 0.074, 95% CI-0.116- 0.264). It is of note 
that those who completed all 3 assessments compared to those who completed the 
baseline assessment and then either the short or long term follow-up, had significantly 
better scores on the SF12-MCS, EQ5D and CESD (table 2). There were no other significant 
effects observed for any other measures of QoL or psychological distress, although there 
were trends in improvements in the TH intervention group. Despite the fact that emotional 
functioning and mastery indicated some significant improvements in the intervention group, 
and change over time in the intervention group compared to the control group, the 
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observed effects did not reach the clinically meaningful magnitudes proposed (all less than 
g= 0·3). 
 
There were no significant effects for trial arm or time in the per protocol analysis (see tables 
5 and 6). Those excluded from the per-protocol analysis were significantly more anxious 
compared those included. Reasons for exclusion included not receiving a pulse oximeter (N 
= 1, having TH installed before completing their baseline assessment (N = 3), completing 
assessments >30 days after scheduled (N=51), not receiving a questionnaire for COPD (N = 
32). 
 
Discussion  
Despite some early concerns that TH may result in reduced QoL this study found no 
evidence for any reduction in patients' QoL, in the longer term. The significant trial arm and 
time interaction effects indicated that those who received TH had better emotional 
functioning and mastery, which improved over time compared to the control group. 
Although these effects were small, there was a consistent trend towards participants 
reporting an improvement in their HRQoL in the intention to treat analysis. 
There were no significant improvements in short term HRQoL or psychological distress.  
Patients needed to have had experience of self-monitoring using TH for approximately 12-
months to show any significant improvements in emotional functioning or mastery. This 
may partly explain the significant differences observed in the ITT analysis, but not the PP 
analysis because participants were more likely to be excluded from the PP analysis due to 
completing the follow-up assessments later than specified in the protocol. This resulted in 
the ITT group having more experience of using TH compared to those included in the PP 
analysis. Another possible factor in the lack of statistically significant findings in the PP 
analysis may have related to the reduced power due to the smaller sample size.   
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The significant trial arm effects in the CCC were not robust in the ACC. The ACC had poorer 
mental health, QoL and greater depression compared to the CCC. Therefore those with 
better QoL and psychological functioning might be able to gain better control over their 
COPD with continued use of TH compared to those with poorer QoL and greater distress, 
who are more likely to attrite before gaining any significant improvements from TH.  
Finally, the results for the COPD cohort of the WSD trial indicated that TH did not improve 
patients generic QoL or psychological distress.  These findings are consistent with the 
combined WSD analysis of the effectiveness of TH on QoL and psychological distress (13). 
This suggests that generic measures are less sensitive to change in response to TH.  
Apart from emotional functioning and mastery there were no significant improvements in 
any of the other measures.  These findings are in contrast to other studies reporting 
improvements at 12-months in symptoms, activity levels, and impact (26), but consistent 
with a more recent trial showing TH was not effective in demonstrating improvements in 
QoL (11). Improvements in disease specific emotional functioning and mastery were only 
apparent at 12-months, but not evident in the short term.  These findings together with the 
ITT compared to PP analysis suggest that any potential, albeit small benefits from TH are not 
immediately apparent and patients need to have experience of using TH before they are 
able to derive any benefits in gaining better mastery and emotional functioning.  
In addition to timing of effects, the data suggest that even though the CRQ is more 
responsive to change compared to the SGRQ (27), there were only two sub-scales that were 
significantly improved in the TH arm. Therefore, the specific outcome measures used needs 
to be considered in reviewing the findings of studies. It is also not advisable to aggregate the 
psychological response to TH with measures of physical symptoms and dyspnoea, as the TH 
intervention may only be effective at changing extra-pulmonary manifestations of COPD 
surrounding control and emotional wellbeing. 
In order to tease out the components of complex TH interventions that are effective, TH 
interventions need to be adequately described so that they can be replicated. It cannot be 
assumed that ‘TH’, telehealthcare and telemonitoring are the same interventions across 
different studies.  Until TH interventions have better descriptions of their content and 
fidelity, there is unlikely to be any clear conclusions regarding effectiveness.  It is 
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noteworthy that the two trials that have found significant effects (9, 10), both included 
weekly telephone calls. This study taken together with Pinnock and colleagues (11) might 
suggest that active monitoring in the absence of weekly telephone contact from clinical staff 
is insufficient to lead to improved outcomes for patients.   
The mediating and moderating variables predicting the heterogeneity in effectiveness need 
to be examined.  Possible moderating variables of TH effectiveness are acute exacerbations 
and recent hospitalisations versus stable disease (26), as well as severity of COPD (11).  
These results have implications for widespread deployment of TH in patients with COPD.    
Strengths and limitations 
Previous research investigating the effects of TH have tended to lack statistical power, have 
weaker methodological designs and unknown generalisability to the NHS in the UK. (4) The 
current clustered RCT addresses many of these methodological limitations. Although the 
samples size achieved were larger than previous trials, following attrition and protocol 
violation the sample was still not quite large enough to reach adequate power. However, 
this is unlikely to change the reported results given that the effect sizes were all less than 
the planned 0.3.  
Future research and implications  
Future research is required to establish what components of TH interventions are effective 
and which are not (e.g. telephone support versus self-monitoring). In order to achieve this 
greater level of understanding, fuller descriptions of TH interventions are required. The 
content of the TH intervention should be designed for the specific outcome measures they 
are targeting. For example, more telephone support may be effective for symptom 
management, whereas self-monitoring may be more effective in improving mastery over 
COPD.  Future work is required to examine immediate versus longer term effectiveness in 
order to determine the optimum duration of TH, as well as the moderating and mediating 
mechanisms of complex TH interventions.   
Conclusions  
12 
 
This is one of the largest pragmatic trials of TH for patients with COPD to date. Providing 
patients with TH tools to monitor and manage their condition remotely was insufficient to 
improve QoL and well-being. However, TH did not reduce QoL nor increase psychological 
distress either. Instead there were small effects for improved emotional functioning and 
mastery over COPD at longer-term follow-up, which were observed in cohorts of patients 
who had the equipment for longer.  
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